Lithera beta agonist begins trial as fat-buster

03/19/2013 | Xconomy

Lithera announced the launch of a 500-patient, Phase II trial of an injectable version of salmeterol xinafoate for localized reduction of abdominal fat tissue. The selective beta agonist is approved in aerosol form as an inhaled asthma treatment.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA